Gold prices steady ahead of Fed decision; weekly weakness noted
Kewaunee Scientific Corp’s (NASDAQ:KEQU) President and CEO, Thomas David Hull III, recently executed several stock sales, according to a filing with the Securities and Exchange Commission. The stock, which has declined nearly 9% over the past week and trades at $44.80, maintains a "GREAT" financial health score according to InvestingPro analysis. On March 21 and March 24, Hull sold a total of 3,213 shares of the company’s common stock. These transactions were conducted at a price range of $45.46 to $48.53 per share, amounting to a total value of approximately $147,228.
Following these sales, Hull retains ownership of 37,916 shares in the company. The transactions were part of routine trading activity and did not involve any equity swaps.
In other recent news, Kewaunee Scientific Corporation has announced an expansion of its share repurchase program, authorizing the repurchase of an additional 100,000 shares of its common stock. This decision follows the completion of Kewaunee’s acquisition of Nu Aire, Inc. on November 1, 2024, which added biological safety cabinets and other critical laboratory equipment to its product portfolio. The share repurchase program, which initially began on September 1, 2023, had 11,176 shares remaining authorized for repurchase. Kewaunee resumed its share repurchase activities on February 28, 2025, and plans to continue them based on favorable market and capital conditions. The company’s management will consider factors such as business capital needs and market conditions when determining the timing and volume of repurchases. The program does not obligate the company to acquire a specific number of shares and may be adjusted at the company’s discretion. This strategic move aligns with Kewaunee’s capital allocation strategy to create shareholder value. The announcement was made via a press release, which included cautionary statements about the forward-looking nature of these plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.